The treatment of metastatic colorectal cancer (mCRC) has become increasingly complex
and nuanced as treatments have evolved over the last decade. During that time, treatment
has evolved from single agent 5-fluorouracil (5FU) chemotherapy to combination
chemotherapy, and more recently to the inclusion of monoclonal antibodies. As such, mCRC
is evolving into a chronic disease in which the median overall survival (mOS) is in excess of
2 years and the 5-year survival is 10%. This review highlights the chemotherapy advances …